Cholera Vaccines

Open Access

Vaccines | Spotlight
Randomized, Placebo-Controlled, Double-Blind Phase 2 Trial Comparing the Reactogenicity and Immunogenicity of a Single Standard Dose to Those of a High Dose of CVD 103-HgR Live Attenuated Oral Cholera Vaccine, with Shanchol Inactivated Oral Vaccine as an Open-Label Immunologic Comparator
Samba O. Sow, Milagritos D. Tapia, Wilbur H. Chen, Fadima C. Haidara, Karen L. Kotloff, Marcela F. Pasetti, William C. Blackwelder, Awa Traoré, Boubou Tamboura, Moussa Doumbia, Fatoumata Diallo, Flanon Coulibaly, Uma Onwuchekwa, Mamoudou Kodio, Sharon M. Tennant, Mardi Reymann, Diana F. Lam, Marc Gurwith, Michael Lock, Thomas Yonker, Jonathan Smith, Jakub K. Simon, Myron M. Levine
Vaccines
The Live Attenuated Cholera Vaccine CVD 103-HgR Primes Responses to the Toxin-Coregulated Pilus Antigen TcpA in Subjects Challenged with Wild-Type Vibrio cholerae
Leslie M. Mayo-Smith, Jakub K. Simon, Wilbur H. Chen, Douglas Haney, Michael Lock, Caroline E. Lyon, Stephen B. Calderwood, Beth D. Kirkpatrick, Mitchell Cohen, Myron M. Levine, Marc Gurwith, Jason B. Harris
VACCINE RESEARCH
A Large Study on Immunological Response to a Whole-Cell Killed Oral Cholera Vaccine Reveals That There Are Significant Geographical Differences in Response and That O Blood Group Individuals Do Not Elicit a Higher Response
T. Ramamurthy, Diane Wagener, Goutam Chowdhury, Partha P. Majumder

Main menu